AU1626199A - A vi-repa conjugate vaccine for immunization against salmonella typhi - Google Patents

A vi-repa conjugate vaccine for immunization against salmonella typhi

Info

Publication number
AU1626199A
AU1626199A AU16261/99A AU1626199A AU1626199A AU 1626199 A AU1626199 A AU 1626199A AU 16261/99 A AU16261/99 A AU 16261/99A AU 1626199 A AU1626199 A AU 1626199A AU 1626199 A AU1626199 A AU 1626199A
Authority
AU
Australia
Prior art keywords
salmonella typhi
conjugate vaccine
immunization against
against salmonella
repa conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16261/99A
Inventor
Zuzana Kossaczka
John B Robbins
Shousun Chen Szu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU1626199A publication Critical patent/AU1626199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU16261/99A 1998-12-04 1998-12-04 A vi-repa conjugate vaccine for immunization against salmonella typhi Abandoned AU1626199A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/025746 WO2000033882A1 (en) 1998-12-04 1998-12-04 A vi-repa conjugate vaccine for immunization against salmonella typhi

Publications (1)

Publication Number Publication Date
AU1626199A true AU1626199A (en) 2000-06-26

Family

ID=22268424

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16261/99A Abandoned AU1626199A (en) 1998-12-04 1998-12-04 A vi-repa conjugate vaccine for immunization against salmonella typhi

Country Status (2)

Country Link
AU (1) AU1626199A (en)
WO (1) WO2000033882A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
US8329184B2 (en) † 2005-06-27 2012-12-11 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
SI2200642T1 (en) 2007-10-19 2012-06-29 Novartis Ag Meningococcal vaccine formulations
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
EP2349520B1 (en) 2008-10-27 2016-05-25 GlaxoSmithKline Biologicals SA Purification method for carbohydrate from group a streptococcus
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
PL2411048T3 (en) 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuvanting meningococcal factor h binding protein
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP2510947B1 (en) 2009-04-14 2016-02-10 GlaxoSmithKline Biologicals SA Compositions for immunising against Staphylococcus aureus
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
CN102724988B (en) 2009-09-30 2014-09-10 诺华股份有限公司 Expression of meningococcal fHBP polypeptides
JP5960055B2 (en) 2009-10-27 2016-08-02 ノバルティス アーゲー Modified meningococcal fHBP polypeptide
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
RU2013144207A (en) 2011-03-02 2015-04-10 Новартис Аг COMBINED VACCINES WITH REDUCED DOSES OF ANTIGEN AND / OR ADJUVANT
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
CN103917245B (en) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 Method for preparing glycoprotein glycoconjugate
CN104080479B (en) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 Carrier molecules including spr0096 and spr2021 antigen
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
BR112014016223A8 (en) 2011-12-29 2017-07-04 Novartis Ag adjuvant combinations of meningococcal h-factor binding proteins
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
JP6324961B2 (en) 2012-09-06 2018-05-16 ノバルティス アーゲー Combination vaccine of serogroup B meningococcus and D / T / P
CN104582718B (en) 2012-10-03 2017-10-24 诺华股份有限公司 Immunogenic composition
WO2014083060A2 (en) 2012-11-30 2014-06-05 Novartis Ag Pseudomonas antigens and antigen combinations
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
CN112999342A (en) 2013-08-24 2021-06-22 巴拉特生物技术国际有限公司 Bacterial vaccines and methods of making the same
EP3782643A1 (en) 2014-02-28 2021-02-24 GlaxoSmithKline Biologicals SA Modified meningococcal fhbp polypeptides
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
EP3448424A4 (en) * 2016-04-25 2019-10-02 National Institute of Immunology A novel conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate
CN106990188B (en) * 2017-06-09 2019-11-15 齐齐哈尔医学院 A kind of high-efficiency liquid chromatography method for detecting of Pseudomonas aeruginosa Exotoxin A
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Also Published As

Publication number Publication date
WO2000033882A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
AU1626199A (en) A vi-repa conjugate vaccine for immunization against salmonella typhi
EP1014787A4 (en) Adjuvant for transcutaneous immunization
AU4781297A (en) Vaccines
EP0682945A3 (en) Oral sustained release preparation.
AU2120197A (en) Salmonella typhimurium vaccine
GB9812613D0 (en) Vaccine
HUP9601466A2 (en) Adjuvants for viral vaccines
AU2001258279A1 (en) Adjuvant for vaccines
AU3154395A (en) Contraceptive vaccine
AU2462899A (en) Live vaccine against brucellosis
AU2769595A (en) Contraceptive vaccine
AU1420897A (en) Conjugate vaccine for (salmonella paratyphi) a
AU4450696A (en) Enhanced immunogenic vaccine
EP0870011A4 (en) Salmonella vaccines
ZA9711565B (en) Vaccine
AU3038697A (en) Meningococcal vaccine
GB0027072D0 (en) Vaccine
IL143808A0 (en) Oral vaccine against diarrhea
GB9704977D0 (en) FIV vaccine
AU5739999A (en) Salmonella typhi vaccine compositions
IL109519A0 (en) Vaccines for oral immunization against infecting agents
ZA98738B (en) Mutant enterotoxin effective as a non-toxic adjuvant for hiv.
AU8877998A (en) Oral vaccine
PL346645A1 (en) IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
AUPM370894A0 (en) Improved adjuvant for vaccines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase